<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418860</url>
  </required_header>
  <id_info>
    <org_study_id>2006-09-025</org_study_id>
    <nct_id>NCT00418860</nct_id>
  </id_info>
  <brief_title>The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent</brief_title>
  <acronym>DATE</acronym>
  <official_title>The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent in the Patients With Coronary Artery Disease (DATE Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to determine whether the dual antiplatelet therapy (aspirin and
      clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in
      terms of death, myocardial infarction, or stent thrombosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of definite stent thrombosis by Academic Research Consortium Proposed Standard</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin, Clopidogrel</intervention_name>
    <description>Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure</description>
    <arm_group_label>A</arm_group_label>
    <other_name>plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinically significant de novo coronary artery disease

          -  Stenting only with EndeavorÂ® stents

          -  The sum of stent length is less than 60 mm for one lesion. The sum of stent length in
             multiple lesions does not matter.

        Exclusion Criteria:

          -  Cardiogenic shock

          -  ST-elevation myocardial infarction within 48 hours of symptom onset

          -  Prior implantation of drug-eluting stents

          -  Left ventricular dysfunction (echocardiographic left ventricular ejection fraction &lt;
             25%)

          -  Stenting both branch of bifurcation lesion

          -  Left main trunk lesion

          -  Graft vessels

          -  Patients who have to receive clopidogrel due to other conditions

          -  Patients who have to receive warfarin, cilostazol or other antiplatelet therapy

          -  Patient with chronic renal failure (S-Cr &gt; 2.0 mg/dl)

          -  Hypersensitivity to clopidogrel or aspirin

          -  Expectant survival less than 1 year

          -  Women who plan to become pregnant

          -  Patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet
             dysfunction, Gastrointestinal or genitourinary bleeding within the prior 3 months)

          -  Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2007</study_first_posted>
  <last_update_submitted>August 10, 2011</last_update_submitted>
  <last_update_submitted_qc>August 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>HC Gwon, MD,PhD / Professor</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>Angioplasty, Transluminal, Percutaneous Coronary</keyword>
  <keyword>Stent thrombosis</keyword>
  <keyword>Zotarolimus-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

